GI50s of PU-H71 and 17-AAG in KSHV- and EBV-positive cell lines
| Cell lines . | PU-H71 . | 17-AAG . | Lymphoma type . | Viral status . |
|---|---|---|---|---|
| GI50 (nM) . | GI50 (nM) . | |||
| BC-1 | 36.9 | 50.9 | PEL | KSHV+/EBV+ |
| BC-2 | 27.1 | 78.6 | PEL | KSHV+/EBV+ |
| BC-5 | 122.7 | 650 | PEL | KSHV+/EBV+ |
| BC-3 | 63.4 | 605.4 | PEL | KSHV+ |
| BCBL-1 | 217.0 | 1009.2 | PEL | KSHV+ |
| VG-1 | 281.5 | 608.9 | PEL | KSHV+ |
| L591 | 337.0 | 952.7 | HL | EBV+ |
| BCKN-1 | 70.9 | 548 | Effusion DLBCL | EBV+ |
| IBL-1 | 87.0 | 833.4 | DLBCL | EBV+ |
| Ly18 | 308.3 | 308.4 | DLBCL | Negative |
| Ly3 | 376.7 | ND | DLBCL | Negative |
| Ly10 | 256.8 | ND | DLBCL | Negative |
| TIVE | 20 561 | ND | Endothelial | Negative |
| TIVE-LTC | 1423 | ND | Endothelial | KSHV+ |
| Cell lines . | PU-H71 . | 17-AAG . | Lymphoma type . | Viral status . |
|---|---|---|---|---|
| GI50 (nM) . | GI50 (nM) . | |||
| BC-1 | 36.9 | 50.9 | PEL | KSHV+/EBV+ |
| BC-2 | 27.1 | 78.6 | PEL | KSHV+/EBV+ |
| BC-5 | 122.7 | 650 | PEL | KSHV+/EBV+ |
| BC-3 | 63.4 | 605.4 | PEL | KSHV+ |
| BCBL-1 | 217.0 | 1009.2 | PEL | KSHV+ |
| VG-1 | 281.5 | 608.9 | PEL | KSHV+ |
| L591 | 337.0 | 952.7 | HL | EBV+ |
| BCKN-1 | 70.9 | 548 | Effusion DLBCL | EBV+ |
| IBL-1 | 87.0 | 833.4 | DLBCL | EBV+ |
| Ly18 | 308.3 | 308.4 | DLBCL | Negative |
| Ly3 | 376.7 | ND | DLBCL | Negative |
| Ly10 | 256.8 | ND | DLBCL | Negative |
| TIVE | 20 561 | ND | Endothelial | Negative |
| TIVE-LTC | 1423 | ND | Endothelial | KSHV+ |
DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin lymphoma; ND, not done.